MaaT Pharma: successful fundraising of 9.1 million euros

MaaT Pharma, a biotechnology company specializing in microbiome therapies, has successfully completed a €9.1 million capital increase. This transaction includes an offering reserved for qualified investors and another for the general public via PrimaryBid. The offering was made at a price of €3.48 per share, thus strengthening the company's financial position.

The funds raised will enable the company to prepare for the commercial launch of Xervyteg®, advance the clinical development of MaaT033 in Europe, and initiate discussions with the FDA for a key study in the United States. MaaT Pharma's financial stability is guaranteed until 2026.

The transaction received significant support from Biocodex, Bpifrance, and Invus Public Entities, representing 49% of the offering. These shares will be admitted to trading on Euronext Paris from November 19, 2025.